Home > Halozyme Therapeutics Salary

Halozyme Therapeutics Salary

  • 42
  • 44
  • 78
Halozyme Therapeutics average salary is $78,196, median salary is $80,000 with a salary range from $57,783 to $95,000.
Halozyme Therapeutics salaries are collected from government agencies and companies. Each salary is associated with a real job position. Halozyme Therapeutics salary statistics is not exclusive and is for reference only. They are presented "as is" and updated regularly.
Total 4 Halozyme Therapeutics Salaries. Sorted by Date, page 1
Ranked By:
Job Title Salaries City Year More info
Calculate how much you could earn

It's FREE. Based on your input and our analysis.     How we do it?

All fields are required for calculation accuracy.

  • We will send you an email to access your personalized report.
  • We won’t share your email address

Halozyme Therapeutics salary is full-time annual starting salary. Intern, contractor and hourly pay scale vary from regular exempt employee. Compensation depends on work experience, job location, bonus, benefits and other factors.

Real Jobs Salary - Salary List
Calculate Your Salary Ranking
Halozyme Therapeutics Jobs
See more Halozyme Therapeutics Jobs»
Search All Jobs

JobCompare – Find open jobs faster
Patents information
Halozyme Therapeutics... Information
  • Halozyme Therapeutics, Inc.
  • Industry: BioTech/Drugs
  • City: San Diego, CA
  • Halozyme Therapeutics, Inc. is a therapeutically driven, development stage biopharmaceutical company dedicated to developing and commercializing recombinant human enzymes for the infertility, ophthalmology, and oncology communities. The company's broad product development portfolio, including expected near- and long-term product offerings, is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's first hyaluronidase enzyme, recombinant human PH20 or rHuPH20, is the platform for three different products, including a medical device, a drug enhancement agent, and a therapeutic biologic. The company's initial products are being developed to offer safer and purer alternatives to existing slaughterhouse-derived extracts that